Could tailored tamoxifen doses keep more breast cancer patients on treatment?

NCT ID NCT07502820

Recruiting now Disease control Sponsor: Karolinska Institutet Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times

Summary

This phase 3 trial tests whether adjusting tamoxifen doses based on individual metabolism can reduce the number of breast cancer patients who stop treatment early due to side effects. About 1,100 premenopausal or perimenopausal women with hormone-sensitive breast cancer will receive either standard or personalized dosing. The goal is to improve adherence and survival outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADJUVANT DRUG THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADJUVANT DRUG THERAPY BREAST CANCER

Contacts and locations

Locations

Capio S:t Görans Sjukhus
NOT_YET_RECRUITING

Stockholm, 112 81, Sweden
S:a Älvsborgs Sjukhus
NOT_YET_RECRUITING

Borås, 501 82, Sweden
Skaraborgs Sjukhus
RECRUITING

Skövde, 549 49, Sweden
Södersjukhuset, Onkologiska kliniken
RECRUITING

Stockholm, 118 61, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.